Drug Profile
WB 007
Alternative Names: WB-007Latest Information Update: 07 Apr 2023
Price :
$50
*
At a glance
- Originator Whitecap Biosciences
- Class Amino alcohols; Antiglaucomas; Antihypertensives; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Small molecules; Thiadiazoles
- Mechanism of Action Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glaucoma; Ocular hypertension
Most Recent Events
- 14 Dec 2022 Whitecap Biosciences completes a phase I/IIa trial in Glaucoma and Ocular hypertension in USA (Ophthalmic) (NCT04149899)